Press release - 11/12/2024 Top German research prize goes to Freiburg cancer researcher The Gottfried Wilhelm Leibniz-Prize 2025 goes to Prof. Dr Robert Zeiser for his outstanding research in haematology and immunology. Zeiser’s research at the University of Freiburg and the Medical Center – University of Freiburg have led, among other things, to new types of cancer therapy that has increased survival rates and the patients’ quality of life.https://www.gesundheitsindustrie-bw.de/en/article/press-release/top-german-research-prize-goes-freiburg-cancer-researcher
NMI spin-off develops theranostics - 02/12/2024 immuneAdvice develops diagnostics to predict the efficacy of immunotherapies Certain types of cancer are already being effectively treated using immunotherapies, though success rates can vary significantly between patients. Researchers from the Natural and Medical Sciences Institute (NMI) in Reutlingen, along with colleagues at the University of Tübingen, are working on a diagnostic approach to accompany therapy, which would rapidly assess whether the treatment is effective or requires adjustment. https://www.gesundheitsindustrie-bw.de/en/article/news/immuneadvice-develops-diagnostics-predict-efficacy-immunotherapies
Press release - 28/11/2024 Molecular biology: New interdisciplinary Research Training Group investigates cellular regulation Cell division, cell differentiation, cell repair and cell death play fundamental roles in the human organism, its development, health and reproduction. Cellular transformation processes are governed by two regulatory mechanisms: chromatin modifications and cell signaling networks. The EpiSignal Research Training Group sheds light on the hitherto little-researched interplay between these two complex systems.https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-biology-new-interdisciplinary-research-training-group-investigates-cellular-regulation
Press release - 26/11/2024 Cellular “power plants” control inflammation Researchers at the Medical Center – University of Freiburg and the University’s CIBSS Cluster of Excellence discover how mitochondria not only produce energy but also influence inflammation.https://www.gesundheitsindustrie-bw.de/en/article/press-release/cellular-power-plants-control-inflammation
Press release - 26/11/2024 Collaborative research centres on kidney and brain prolonged On 25 November, the German Research Foundation (DFG) announced the continued funding of two existing Collaborative Research Centres (CRC) at the University of Freiburg’s Faculty of Medicine. In CRC 1453 Nephrogenetics (NephGen), doctors and researchers are using genetic information to search for mechanisms underlying kidney diseases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/collaborative-research-centres-kidney-and-brain-prolonged
Press release - 20/11/2024 Millions in federal funding: customized 3D printing for patients in oral and maxillofacial surgery The German Federal Ministry of Education and Research (BMBF) is currently funding a project at the Department of Oral and Maxillofacial Surgery at Heidelberg University Hospital with around 1.2 million euros. The aim is to use 3D printing technology to produce individualized implants directly in the clinic, thus enabling faster, more efficient and more precise patient-specific care. To this end, the UKHD is working with an industrial partner.https://www.gesundheitsindustrie-bw.de/en/article/press-release/millions-federal-funding-customized-3d-printing-patients-oral-and-maxillofacial-surgery
Press release - 20/11/2024 New bioengineering approaches for the automated production of complex organoids The reproducible and precise production of complex organoid models to simulate human organ malfunctions is the focus of an interdisciplinary research project at Heidelberg University. A research team from the life and engineering sciences is looking to combine the engineering of molecular systems with machine learning and automated production methods. https://www.gesundheitsindustrie-bw.de/en/article/press-release/neue-ansaetze-des-bio-engineering-fuer-die-automatisierte-herstellung-komplexer-organoide
Press release - 15/11/2024 Patient association raises 10,000 euros for work on PURA syndrome - Donation for research into rare neuronal developmental disorder at Ulm University PURA syndrome is a rare developmental disorder of the brain for which there is currently no cure. The patient association PURA Syndrome Germany was founded last year. Since then, the affected families have been collecting donations with great dedication – and have decided to donate the majority of this money to research into the syndrome at Ulm University. https://www.gesundheitsindustrie-bw.de/en/article/press-release/patient-association-raises-10000-euros-work-pura-syndrome-donation-research-rare-neuronal-developmental-disorder-ulm-university
Press release - 14/11/2024 Novel method for fighting tumors Making existing cancer therapy more efficient while significantly reducing the side effects on healthy tissue - this is the aim of a project at Aalen University. It is being funded with one million euros from the Carl Zeiss Foundation. The biophysicist and his team are developing innovative nanoparticles made of gold. The particles use radiotherapy and chemotherapy simultaneously and kill the cancer cells in a targeted manner.https://www.gesundheitsindustrie-bw.de/en/article/press-release/novel-method-for-fighting-tumors
Advancing quantum technology into real-world applications - 06/11/2024 QSens: BMBF future cluster brings quantum sensors of the future into medicine The BMBF-funded future cluster ‘QSens – Quantum Sensors of the Future’ is developing ultra-sensitive sensors that could open up new options in medicine, enabling faster drug research, more accurate diagnostics and improved rehabilitation. The universities of Stuttgart and Ulm are actively working with 17 industry partners to put these cutting-edge innovations to immediate practical use.https://www.gesundheitsindustrie-bw.de/en/article/news/qsens-bmbf-future-cluster-brings-quantum-sensors-future-medicine
Press release - 05/11/2024 Heidelberg scientist receives highly endowed EC synergy grant Heidelberg scientist Dr Venera Weinhardt has received an ERC Synergy Grant for a pioneering biomedical research project. The European Research Council (ERC) is granting this funding to advance soft X-ray microscopy. This imaging technique along with other innovations will be used to investigate the hepatitis E virus. https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-scientist-receives-highly-endowed-ec-synergy-grant
Press release - 30/10/2024 Diabetes switch in DNA: Non-coding region in the genome influences ONECUT1 gene They are underestimated genetic control elements: it is known that changes in the genome can trigger diabetes. But now researchers at the University Hospital Ulm and the INSERM Cochin Institute in Paris have shown that a previously under-researched region of the genome also plays a crucial role in the development of this disease. https://www.gesundheitsindustrie-bw.de/en/article/press-release/diabetes-switch-dna-non-coding-region-genome-influences-onecut1-gene
NMI project WOUNDSENS - 23/10/2024 Wound monitoring using sensory nanofibres Monitoring the condition of chronic, non-healing wounds requires wound dressings to be changed at short, regular intervals. In the EU-funded WOUNDSENS project, researchers at the NMI in Reutlingen are using electrospinning to produce novel types of wound dressings. These consist of biosensory fibres that send information about the condition of the wound to the outside, thereby improving inflammation detection.https://www.gesundheitsindustrie-bw.de/en/article/news/wound-monitoring-using-sensory-nanofibres
Press release - 25/09/2024 How developmental signals can contribute to Genomic Mosaicism Certain developmental signals play a significant role in maintaining our genetic blueprints. They prevent alterations in the genome, known as mosaicism. The underlying biological mechanism helps the DNA to produce an identical copy of itself during cell division using the original genetic blueprint. However, it can also contribute to genomic mosaicism during nerve cell development.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-developmental-signals-can-contribute-genomic-mosaicism
Press release - 23/09/2024 Carl Zeiss Foundation supports early career research group for biohybrid neuroimplants Dr Simon Binder has been awarded a five-year, 1.5 million euro grant from the Carl Zeiss Foundation for his research into novel neuroimplants. Binder will establish the early career research group ‘Biohybrid Neuroimplants based on Soft Hydrogel Electrodes’ at the University of Freiburg. It is affiliated with the research institutions BrainLinks-BrainTools.https://www.gesundheitsindustrie-bw.de/en/article/press-release/carl-zeiss-foundation-supports-early-career-research-group-biohybrid-neuroimplants
Press release - 19/09/2024 Quality standards for looking into the tumor genome Personalized medicine with individually tailored therapies is becoming more a reality in cancer. This requires a look into the genetic material of tumors, a molecular diagnostic tumor profile. A research group from the German Network for Personalized Medicine (DNPM) has recorded the quality standards according to which genome analyses are carried out in Germany. The data is a prerequisite for integrating gene sequencing into routine care. https://www.gesundheitsindustrie-bw.de/en/article/press-release/quality-standards-looking-tumor-genome
Press release - 18/09/2024 Future cluster QSens starts the second round of funding In the “Cluster4Future” QSens of the Universities of Stuttgart and Ulm, scientists, companies and start-ups are researching quantum sensors with a wide range of potential applications. The Federal Ministry of Education and Research is funding QSens for a further three years as part of “Clusters4Future”.https://www.gesundheitsindustrie-bw.de/en/article/press-release/future-cluster-qsens-starts-second-round-funding
Press release - 17/09/2024 Five new cross-border doctoral networks at Universität Heidelberg Five transnational and cross-institutional doctoral networks at Heidelberg University are being funded as part of the “Marie Skłodowska-Curie Actions”. They work together on current scientific topics with high innovation potential. Ruperto Carola coordinates an MSCA Doctoral Network on artificial intelligence in physics, two networks in medicine, life sciences and engineering. https://www.gesundheitsindustrie-bw.de/en/article/press-release/five-new-cross-border-doctoral-networks-universitat-heidelberg
Press release - 11/09/2024 Researchers combine the power of artificial intelligence and the wiring diagram of a brain to predict brain cell activity Scientists have long sought ways to simulate the neural networks in the brain with computers in order to understand how it works. Now, researchers have combined new measurements of the wiring diagrams of the fruit fly with artificial intelligence methods to build a neural network that can do what few thought possible: To predict the activity of individual neurons without making a single measurement in a living brain. https://www.gesundheitsindustrie-bw.de/en/article/press-release/researchers-combine-power-artificial-intelligence-and-wiring-diagram-brain-predict-brain-cell-activity
Press release - 09/09/2024 New Molecular Engineering Technique allows for complex Organoids A new molecular engineering technique can precisely influence the development of organoids. Microbeads made of specifically folded DNA are used to release growth factors or other signal molecules inside the tissue structures. This gives rise to considerably more complex organoids that imitate the respective tissues much better and have a more realistic cell mix than before. https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-molecular-engineering-technique-allows-complex-organoids
Press release - 14/08/2024 New vaccine against cervical cancer combines prophylactic and therapeutic activities Scientists at the German Cancer Research Center (DKFZ) have developed a completely new vaccination concept. The vaccine is inexpensive and protects mice against almost all cancer-causing HPV types. In addition to preventing new infections, the vaccine also triggers cellular immune responses against HPV-infected cells and may therefore also have a therapeutic effect against existing infections.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-vaccine-against-cervical-cancer-combines-prophylactic-and-therapeutic-activities
Press release - 13/08/2024 Peptide Boronic Acids: New Prospects for Immunology A cutting-edge chemical process is the first to make it possible to quickly and easily produce modified peptides with boronic acids. As part of this work, scientists managed to synthesize a large number of different biologically active peptide boronic acids and investigate their properties. They open up new possibilities in the young research field of synthetic immunology and could go on to be used primarily in immunotherapy. https://www.gesundheitsindustrie-bw.de/en/article/press-release/peptide-boronic-acids-new-prospects-immunology
Start-up Cerebri GmbH - 05/08/2024 Comprehensive EEG supply thanks to telemedicine Fewer and fewer patients are getting timely access to electroencephalograms, as the process of measuring brain activity and interpreting the results requires specific expertise. Cerebri GmbH, a newly established Tübingen-based company, aims to address this issue by offering user-friendly EEG caps and providing rapid, location-independent and top-tier diagnostics by experts.https://www.gesundheitsindustrie-bw.de/en/article/news/comprehensive-eeg-supply-thanks-telemedicine
Press release - 01/08/2024 Targeted therapy for cancer of unknown primary (Cup) Encouraging results from a large international study led by Heidelberg have recently been published in the journal “Lancet”: The genetic material of cancer cells with unknown tissue of origin contains numerous targets for specific drugs that are already available and have been developed to treat other forms of cancer. These suppressed the disease in CUP patients for significantly longer than chemotherapy.https://www.gesundheitsindustrie-bw.de/en/article/press-release/targeted-therapy-cancer-unknown-primary-cup
Research association - 24/07/2024 SPI-MP: pioneer in personalised medical technology Every person is unique – even when they are ill. This is why many approaches to personalised medicine have been under development. The Stuttgart Partnership Initiative - Mass Personalization (SPI-MP), which focuses on basic research into fabrication and biomaterial technologies for personalised biomedical systems, is at the heart of such research work. The projects range from artificial knee joint cartilage to state-of-the-art stroke diagnostics.https://www.gesundheitsindustrie-bw.de/en/article/news/spi-mp-pioneer-personalised-medical-technology